# Core D In vitro Screening

> **NIH NIH U19** · HACKENSACK UNIVERSITY MEDICAL CENTER · 2021 · $365,302

## Abstract

Abstract 
The microbial In Vitro Screening (IVS) Core will provide comprehensive susceptibility testing 
encompassing a range of assays for candidate compounds of the five projects. The projects 
represent various stages in development and require individual consideration. However, a 
common thread through all 5 projects is the requirement for whole cell screening. The resources 
and expertise of the IVS Core include macrophage infection model and intracellular susceptibility, 
concentration-dependent killing versus time-dependent killing, small colony variants, anti-biofilm 
efficacy, serum shift experiments, stationary phase or “one hundred day old” cultures, resistant 
mutant generation and analysis, and drug combination analysis. Drug response relationships to 
assess mutant formation/prevention and other advanced analysis are also available. Compound 
purity will be confirmed working in conjunction with the Medicinal Chemistry Core (Core B). Data 
conformity and storage will be handled and shared using the Collaborative Drug Discovery, Inc. 
software program (see Data Sharing). The organisms in the Screening Core’s collection include 
twenty-eight species of pathogens. The laboratories of Dr. Connell and Dr. Barry Kreiswirth 
(PHRI) provide extensive collections of clinical strains, well characterized for antibiotic resistance, 
assembled in collaboration with private, public and VA hospitals in the New York/New Jersey 
metropolitan area, as well as hospitals throughout the world, that will serve in later stages of the 
project to define resistance profiles. BSL2, BSL3 and Select Agent BSL3 laboratories are 
provided for the safe use of this extensive strain collection. The team assembled to carry out 
these in vitro assays has a combined experience of over 65 years in bacterial drug discovery and 
analysis of antibiotic susceptibility and resistance. The group's medium throughput experience 
with high precision and fast turnaround is a significant and essential contribution to the overall 
project’s success. 
!

## Key facts

- **NIH application ID:** 10138980
- **Project number:** 5U19AI142731-03
- **Recipient organization:** HACKENSACK UNIVERSITY MEDICAL CENTER
- **Principal Investigator:** BARRY Neal KREISWIRTH
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $365,302
- **Award type:** 5
- **Project period:** 2019-05-01 → 2024-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10138980

## Citation

> US National Institutes of Health, RePORTER application 10138980, Core D In vitro Screening (5U19AI142731-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10138980. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*